Brief: Northwest Biotherapeutics Inc announces registered direct offering
21/10/2016 14:45
Oct 21 (Reuters) -
* Northwest Biotherapeutics Inc announces registered direct
offering
* Northwest Biotherapeutics Inc - Definitive agreement with
an institutional investor for a registered direct offering with
gross proceeds of about $5 million
* Northwest Biotherapeutics Inc - Proceeds of offering will
be used in connection with upcoming Phase II clinical trials
* Northwest Biotherapeutics Inc - Company has agreed to sell
to investor up to 14 million shares of company's common stock at
a purchase price of $0.38 per share
Source text for Eikon: ID:nPn9Tkplma
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB